key: cord-0690509-3zofwkbs
authors: Lallas, Aimilios; Kyrgidis, Athanassios; Manoli, Sofia-Magdalini; Papageorgiou, Chryssoula; Lallas, Konstantinos; Sotiriou, Elena; Vakirlis, Efstratios; Sidiropoulos, Theodoros; Ioannides, Dimitrios; Apalla, Zoe
title: Delayed skin cancer diagnosis in 2020 due to the COVID-19-related restrictions: data from an institutional registry
date: 2021-05-27
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.05.021
sha: 10a794fcc206fe7f51dd7a211d0d53b8de726f45
doc_id: 690509
cord_uid: 3zofwkbs

[Figure: see text]

The analytical results are shown in Table 1 and Figure 1 . The total number of new skin 47 cancers was 30.1% lower than the expected. The reduction was 36.4%, 22.3% and 44.8% for 48 melanoma, BCC and SCC, respectively. Melanoma and BCC patients were significantly younger at 49 the time of diagnosis in 2020 than in previous years, and a similar trend was found for SCC, 50 reflecting the increased concerns regarding COVID-19 infection among elderly individuals. 51

Similarly, the higher than expected female representation may mirror the increased fear of severe 52 COVID-19 consequences among males. 53 A substantially lower than expected proportion of melanomas was diagnosed at stage 0 and 54 IA and a significantly higher than expected percentage at stage IIC, III and IV. Notably, the number 55 of new melanomas diagnosed in patients with previous melanoma history was slightly higher than 56 expected, suggesting that the high awareness in this group prevented diagnostic delays. 57 and mortality, due to pandemic-related disruptions were expressed early in the course of the 59 COVID-19 outbreak. 2 Our results confirm this fear by revealing a reduced number of diagnosed 60 skin cancers and a trend towards a more advanced melanoma stage at diagnosis. A previous study in 61 the US reported significantly fewer and more advanced melanomas during 2 months in 2020 than in 62 the same period in 2019. 5 Similar observations have been reported for other common cancers. 1-3 63

Our results indicate that skin cancer diagnosis due to COVID-19-related restrictions is 64 delayed. Future studies should assess whether this affects melanoma morbidity and mortality. The lockdown intervals were characterized by an evident divergence between observed and 119 expected diagnoses. 120 J o u r n a l P r e -p r o o f

The impact of the

UK: a national, 88 population-based, modelling study

Declines in Cancer Screening During COVID-19 Pandemic

Second primary 92 melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring

The 95